Kros JM - Search Results

1

Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors.

Lassman AB, Hoang-Xuan K, Polley MC, Brandes AA, Cairncross JG, Kros JM, Ashby LS, Taphoorn MJB, Souhami L, Dinjens WNM, Laack NN, Kouwenhoven MCM, Fink KL, French PJ, Macdonald DR, Lacombe D, Won M, Gorlia T, Mehta MP, van den Bent MJ. Lassman AB, et al. Among authors: kros jm. J Clin Oncol. 2022 Aug 10;40(23):2539-2545. doi: 10.1200/JCO.21.02543. Epub 2022 Jun 22. J Clin Oncol. 2022. PMID: 35731991 Free PMC article.

2

The effect of dexamethasone on the uptake of cisplatin in 9L glioma and the area of brain around tumor.

Straathof CS, van den Bent MJ, Ma J, Schmitz PI, Kros JM, Stoter G, Vecht CJ, Schellens JH. Straathof CS, et al. Among authors: kros jm. J Neurooncol. 1998 Mar;37(1):1-8. doi: 10.1023/a:1005835212246. J Neurooncol. 1998. PMID: 9525832

3

Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group.

van den Bent MJ, Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HG, Taphoorn MJ, Zonnenberg BA, Tijssen CC, Twijnstra A, Punt CJ, Boogerd W. van den Bent MJ, et al. Among authors: kros jm. Neurology. 1998 Oct;51(4):1140-5. doi: 10.1212/wnl.51.4.1140. Neurology. 1998. PMID: 9781544

4

Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas.

van den Bent MJ, Schellens JH, Vecht CJ, Sillevis Smit PA, Loosveld OJ, Ma J, Tijssen CC, Jansen RL, Kros JM, Verweij J. van den Bent MJ, et al. Among authors: kros jm. Eur J Cancer. 1998 Sep;34(10):1570-4. doi: 10.1016/s0959-8049(98)00138-5. Eur J Cancer. 1998. PMID: 9893630 Clinical Trial.

5

Glial fibrillary acidic protein and its fragments discriminate astrocytoma from oligodendroglioma.

Luider TM, Kros JM, Sillevis Smitt PA, van den Bent MJ, Vecht CJ. Luider TM, et al. Among authors: kros jm. Electrophoresis. 1999 Apr-May;20(4-5):1087-91. doi: 10.1002/(SICI)1522-2683(19990101)20:4/5<1087::AID-ELPS1087>3.0.CO;2-6. Electrophoresis. 1999. PMID: 10344289

6

Genetic aberrations in oligodendroglial tumours: an analysis using comparative genomic hybridization (CGH).

Kros JM, van Run PR, Alers JC, Beverloo HB, van den Bent MJ, Avezaat CJ, van Dekken H. Kros JM, et al. J Pathol. 1999 Jul;188(3):282-8. doi: 10.1002/(SICI)1096-9896(199907)188:3<282::AID-PATH355>3.0.CO;2-S. J Pathol. 1999. PMID: 10419597

7

Temozolomide chemotherapy in recurrent oligodendroglioma.

van den Bent MJ, Keime-Guibert F, Brandes AA, Taphoorn MJ, Kros JM, Eskens FA, Carpentier AF. van den Bent MJ, et al. Among authors: kros jm. Neurology. 2001 Jul 24;57(2):340-2. doi: 10.1212/wnl.57.2.340. Neurology. 2001. PMID: 11468326

8

Genetic aberrations in gliomatosis cerebri support monoclonal tumorigenesis.

Kros JM, Zheng P, Dinjens WN, Alers JC. Kros JM, et al. J Neuropathol Exp Neurol. 2002 Sep;61(9):806-14. doi: 10.1093/jnen/61.9.806. J Neuropathol Exp Neurol. 2002. PMID: 12230327

9

Analysis of immunoglobulin H gene rearrangement by polymerase chain reaction in primary central nervous system lymphoma.

Kros JM, Bagdi EK, Zheng P, Hop WC, Driesse MJ, Krenacs L, Dinjens WN. Kros JM, et al. J Neurosurg. 2002 Dec;97(6):1390-6. doi: 10.3171/jns.2002.97.6.1390. J Neurosurg. 2002. PMID: 12507138

10

Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.

van den Bent MJ, Looijenga LH, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L, Sillevis Smitt PA, Jenkins RB, Kros JM. van den Bent MJ, et al. Among authors: kros jm. Cancer. 2003 Mar 1;97(5):1276-84. doi: 10.1002/cncr.11187. Cancer. 2003. PMID: 12599236 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

312 results

Search Page